From screening to treatment, the continuum of lung cancer reflects unequal access and delivery, with more vulnerable patients less able to receive high-quality care. Despite great advances in lung cancer care (eg, screening and nodule programs to identify early-stage disease and immune-mediated and targeted therapies for advanced-stage disease), disparities persist both in the United States and globally. In this narrative review, the spectrum of disparities that influence lung cancer care on a national scale, including race, ethnicity, age, socioeconomic status, geographic location, and insurance access, are explored. The review focuses on how disparities impact screening efforts and lung cancer treatments. Where data are available, trends on a global scale are addressed. Potential solutions are offered to address recognized disparities, primarily by identifying pertinent social determinants of health and launching multipronged interventions to improve the care of all patients with lung cancer.

Limited data exist to inform and appropriately counsel female lung transplant (LuT) recipients regarding pregnancy after transplantation.

A 7-year-old girl was referred to our vascular anomaly center for further evaluation of multiple lung nodules. These nodules were incidentally detected on a CT scan during hospitalization for treatment of mycoplasma pneumonia at another hospital. The biopsy results suggested the possibility of vascular tumors. Physical examination revealed clear breath sounds without rales. Furthermore, no skin lesions or other positive signs were observed. The patient was not receiving supplemental oxygen. Before she came to our center, the patient had received antibiotic treatment for mycoplasma pneumonia. The CT scan after recovery revealed that the multiple nodules in both lungs persisted despite the resolution of the infection.

With rising interest in centralized lung cancer screening (LCS), synthesizing evidence to estimate its impact on annual adherence is critical for aligning practice with guideline recommendations.

Patients with interstitial lung disease (ILD) often receive care from general pulmonologists because geographic and financial barriers limit access to specialized care centers. However, many graduating pulmonary fellows lack confidence in managing patients with ILD. Refining ILD education in pulmonary fellowship could address this gap, but what trainees must learn is not defined currently.

More than 600,000 adults in the United States experience an out-of-hospital or in-hospital cardiac arrest each year. Following resuscitation from cardiac arrest, most patients receive mechanical ventilation. The oxygenation target that optimizes neurologic outcomes following cardiac arrest is uncertain.

Pulmonary arterial hypertension (PAH) is a complex cardiopulmonary disease associated with exertional dyspnea and impaired health-related quality of life (HRQOL) despite medical therapy. Pulmonary rehabilitation (PR), a supervised exercise program for patients with chronic lung disease, improves symptoms, HRQOL, and exercise capacity. Despite these benefits, there is a paucity of data regarding PR in PAH.

It remains challenging to safely and reliably biopsy peripheral pulmonary lesions (PPLs). Robotic-assisted bronchoscopy (RAB) is gaining adoption for navigation to PPLs. However, evidence from large studies remains limited.

The bidirectional relationship between frailty and COPD is documented. However, longitudinal studies examining the combined effects of genetic predisposition and preserved ratio impaired spirometry (PRISm) on frailty in COPD development are lacking.

Long-term real-world data on clinical remission in patients with severe eosinophilic asthma (SEA) receiving biologics are lacking. We describe clinical remission over 2 years in patients with SEA receiving benralizumab.

Studies have reported estimates of the economic and health burden of COPD. They have been limited largely to current-day estimates or relatively short-term future projections.

Among 1 billion patients worldwide with OSA, 90% remain undiagnosed. The main barrier to diagnosis is the overnight polysomnogram, which requires specialized equipment, skilled technicians, and inpatient beds available only in tertiary sleep centers. Recent advances in artificial intelligence (AI) have enabled OSA detection using breathing sound recordings.

A 70-year-old woman who formerly used tobacco was referred for evaluation of a lung nodule incidentally discovered during hematologic follow-up. Her medical history was notable for a stage IV follicular lymphoma (G2/G3A stage IV, for pleural and perinephric involvement, FLIPI4) in September 2022, for which she received 6 courses of obinutuzumab plus bendamustine. After the second cycle of therapy, an increase in transaminases was detected; the subsequent diagnostic workup showed a positive real-time polymerase chain reaction blood test for human herpesvirus 6 DNA with more than 13,000 copies/mL. The human herpesvirus 6 infection was successfully treated with acyclovir, followed by normalization of liver enzymes. The treatment was then completed regularly, obtaining a complete metabolic response. One month after completing therapy, the patient developed systemic cytomegalovirus infection with associated pneumonia, requiring 3 weeks of hospitalization. Considering the severity of the infectious event, a further maintenance with obinutuzumab was excluded. Persistent cytomegalovirus-DNA levels necessitated valganciclovir. Sustained neutropenia partially improved with granulocyte colony-stimulating factor administration.

Dysregulation of the mechanistic target of rapamycin (mTOR) signaling pathway rarely results in parenchymal lung disease, prototypically multifocal multinodular pneumocyte hyperplasia (MMPH) and lymphangioleiomyomatosis (LAM). Although LAM can occur sporadically, to our knowledge, MMPH has not previously been described independent of tuberous sclerosis complex (TSC), a syndrome caused by germline mutations in the tumor suppressor genes TSC1 or TSC2. We report the case of a man with a history of multiple malignancies who presented with incidental chest imaging findings of innumerable ground-glass nodules and several air-filled cysts, offering a diagnostic challenge. Histopathologic findings on lung biopsy identified nodular foci of pneumocyte hyperplasia with negative Human Melanoma Black-45 staining. Next-generation DNA sequencing of the tissue showed a previously described gain-of-function mutation in MTOR. We propose that this patient's TSC-like pulmonary disease is a direct result of this mutation, a novel finding that underscores the role of Next-generation DNA sequencing in cryptic histopathology.

Airway mucus plugs are frequently identified on CT scans of patients with COPD and are associated with worse airflow obstruction and higher mortality. However, the association between airway mucus plugs and the risk of acute exacerbation of COPD (AECOPD) has not been extensively studied.

Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are chronic fibrosing interstitial lung diseases associated with irreversible loss of lung function and early mortality. Admilparant (BMS-986278) is an oral lysophosphatidic acid receptor 1 antagonist under development for treatment of IPF and PPF.